Biomarker Panels for Predicting Progression of Kidney Disease in Acute Kidney Injury Survivors
Clinical Journal of the American Society of Nephrology · 2025-03 · 20 (3) · 337-345
DOI: 10.2215/cjn.0000000622 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Journal of the American Society of Nephrology, online erschienen am 13.12.2024. Verfasst von Steven Menez und 13 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NHLBI NIH HHS, National Institute of Diabetes and Digestive and Kidney Diseases.
Abstract (Originalsprache)
Key Points Clinical characteristics and biomarkers after hospital discharge can predict major adverse kidney events among AKI survivors. Clinical impact plots based on parsimonious prediction models illustrate the potential to optimize post-AKI care by identifying high-risk patients.
Background
AKI increases the risk of CKD. We aimed to identify combinations of clinical variables and biomarkers that predict long-term kidney disease risk after AKI.
Methods
We analyzed data from a prospective cohort of 723 hospitalized patients with AKI in the Assessment, Serial Evaluation, and Subsequent Sequelae of AKI study. Using machine learning, we investigated 75 candidate predictors including biomarkers measured at 3-month postdischarge follow-up to predict major adverse kidney events (MAKEs) within 3 years, defined as a decline in eGFR ≥40%, development of ESKD, or death.
Results
The mean age of study participants was 64±13 years, 68% were male, and 79% were of White race. Two hundred four patients (28%) developed MAKEs over 3 years of follow-up. Random forest and least absolute shrinkage and selection operator penalized regression models using all 75 predictors yielded area under the receiver-operating characteristic curve (AUC) values of 0.80 (95% confidence interval [CI], 0.69 to 0.91) and 0.79 (95% CI, 0.68 to 0.90), respectively. The most consistently selected predictors were albuminuria, soluble TNF receptor-1, and diuretic use. A parsimonious model using the top eight predictor variables showed similarly strong discrimination for MAKEs (AUC, 0.78; 95% CI, 0.66 to 0.90). Clinical impact utility analyses demonstrated that the eight-predictor model would have 55% higher efficiency of post-AKI care (number needed to screen/follow-up for a MAKE decreased from 3.55 to 1.97). For a kidney-specific outcome of eGFR decline or ESKD, a four-predictor model showed strong discrimination (AUC, 0.82; 95% CI, 0.68 to 0.96).
Conclusions
Combining clinical data and biomarkers can accurately identify patients with high-risk AKI, enabling personalized post-AKI care and improved outcomes.
Autor:innen und Institutionen
- Division of Nephrology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.
- Department of Biostatistics, University of Washington, Seattle, Washington.
- Section of Nephrology, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut.
- Division of Nephrology, Department of Medicine, University of California San Francisco, San Francisco, California.
- Division of Research, Kaiser Permanente Northern California, Oakland, California.
- Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California.
ORCID-Profile: Kathleen F Kerr, Si Cheng, David Hu, Heather Thiessen-Philbrook, Dennis G Moledina, Alan S Go, T Alp Ikizler, James S Kaufman, Jonathan Himmelfarb, Chirag R Parikh
Förderung
- NIDDK NIH HHS
- NHLBI NIH HHS
- National Institute of Diabetes and Digestive and Kidney Diseases
Zitieren
APA
Menez, S., Kerr, K. F., Cheng, S., Hu, D., Thiessen-Philbrook, H., Moledina, D. G., Mansour, S. G., Go, A. S., Ikizler, T. A., Kaufman, J. S., Kimmel, P. L., Himmelfarb, J., Coca, S. G., & Parikh, C. R. (2025). Biomarker Panels for Predicting Progression of Kidney Disease in Acute Kidney Injury Survivors. Clinical Journal of the American Society of Nephrology, 20(3), 337-345. https://doi.org/10.2215/cjn.0000000622
Vancouver
Menez S, Kerr KF, Cheng S, Hu D, Thiessen-Philbrook H, Moledina DG, et al. Biomarker Panels for Predicting Progression of Kidney Disease in Acute Kidney Injury Survivors. Clinical Journal of the American Society of Nephrology. 2025;20(3):337-345. doi:10.2215/cjn.0000000622
BibTeX
@article{Menez2025,
author = {Menez, Steven and Kerr, Kathleen F and Cheng, Si and Hu, David and Thiessen-Philbrook, Heather and Moledina, Dennis G and Mansour, Sherry G and Go, Alan S and Ikizler, T Alp and Kaufman, James S and Kimmel, Paul L and Himmelfarb, Jonathan and Coca, Steven G and Parikh, Chirag R},
title = {Biomarker Panels for Predicting Progression of Kidney Disease in Acute Kidney Injury Survivors},
journal = {Clinical Journal of the American Society of Nephrology},
year = {2025},
volume = {20},
number = {3},
pages = {337--345},
doi = {10.2215/cjn.0000000622}
}
EUVIMED